Drugs / BIIB095
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04106050 | Sep 2020 → Jan 2022 | diabetic polyneuropathy | Biogen | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03454126 | Mar 2018 → Apr 2019 | — | Biogen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04106050 ↗ |
| Modality | Small molecule | — CHEMBL3341997 ↗ |
| Route | Oral | “single- and multiple-ascending oral doses of BIIB095” NCT03454126 ↗ |